Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma

Survival of activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL) is driven by chronic B cell receptor (BCR) signaling that activates the canonical NF-κB pathway. Inhibition of BTK by Ibrutinib has been shown to kill ABC DLBCL cells that carry activating mutations in the BCR adapto...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagel, Daniel, Bognar, Miriam, Eitelhuber, Andrea C., Kutzner, Kerstin, Vincendeau, Michelle, Krappmann, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747221/
https://www.ncbi.nlm.nih.gov/pubmed/26540570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747221/
https://www.ncbi.nlm.nih.gov/pubmed/26540570

Ejemplares similares